Clinical usefulness of prognostic biomarkers in optic neuritis-Reference-Cited by-同舟云学术

Clinical usefulness of prognostic biomarkers in optic neuritis

Published:2018-02-06 Issue:4 Volume:25 Page:614-618
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Tejeda-Velarde A.¹²^ORCID,Costa-Frossard L.²³,Sainz de la Maza S.²³,Carrasco Á.¹,Espiño M.¹²,Picón C.¹²,Toboso I.¹²,Walo P. E.¹,Lourido D.⁴,Muriel A.⁵,Álvarez-Cermeño J. C.²³⁶,Villar L. M.¹²^ORCID

Affiliation:

1. Immunology Department; IRYCIS; Hospital Universitario Ramón y Cajal; Madrid Spain

2. The Spanish Network of Multiple Sclerosis (REEM); Spain

3. Neurology Department; IRYCIS; Hospital Universitario Ramón y Cajal; Madrid Spain

4. Radiology Department; IRYCIS; Hospital Universitario Ramón y Cajal; Madrid Spain

5. Biostatistics Unit; IRYCIS CIBERESP; Hospital Universitario Ramón y Cajal; Madrid Spain

6. Medicine Department; Alcalá University; Alcalá de Henares Spain

Funder

Fondo para la Investigación Sanitaria, Instituto de Salud Carlos III

Instituto de Salud Carlos III

Ministerio de Economía y Competitividad

Federación Española de Enfermedades Raras

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.13553/fullpdf

Reference20 articles.

1. Optic neuritis, its differential diagnosis and management;Hoorbakht;Open Ophthalmol J,2012

2. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up;Optic Neuritis Study Group;Arch Neurol,2008

3. Vision disturbances in multiple sclerosis;Costello;Semin Neurol,2016

4. Is optic neuritis more benign than other first attacks in multiple sclerosis?;Tintoré;Ann Neurol,2005

5. Defining high, medium and low impact prognostic factors for developing multiple sclerosis;Tintore;Brain,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study;Neurology and Therapy;2023-10-10

2. Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment;Neurology and Therapy;2023-09-08

3. Cut-off evaluation of intrathecal oligoclonal bands of IgM in relapsing-remitting multiple sclerosis; a retrospective study;Multiple Sclerosis and Related Disorders;2022-12

4. Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis;Frontiers in Immunology;2022-08-10

5. Cerebrospinal Fluid IgM and Oligoclonal IgG Bands in Multiple Sclerosis: A Meta-Analysis of Prevalence and Prognosis;Brain Sciences;2021-10-29